Scorpius Holdings Inc. (SCPX)
AMEX AMEX Primary Summary
Why Is Scorpius (SCPX) Stock Down 79% Today?
Scorpius (NYSEMKT: SCPX ) stock is taking a beating on Wednesday after the company provided details on a public offering. Scorpius has announced that it will sell 12.5 million shares of SCPX stock in this public offering.
Scorpius Holdings Inc. (SCPX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Scorpius Holdings Inc. ever had a stock split?
Scorpius Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeff A. Wolf CEO | AMEX Exchange | 42237K508 CUSIP |
| US Country | 91 Employees | - Last Dividend | 21 Jan 2025 Last Split | - IPO Date |
Overview
Scorpius Holdings, Inc., along with its subsidiary Scorpius BioManufacturing, stands as a comprehensive contract development and manufacturing organization (CDMO) dedicated to the pharmaceutical sector. Initially named NightHawk Biosciences, Inc., the company underwent a rebranding in February 2024 to its current identity. Established in 2008 and headquartered in Morrisville, North Carolina, Scorpius Holdings, Inc. emphasizes its commitment to supporting clinical and commercial drug substance manufacturing. It also engages in release and stability testing, marking a significant footprint in the biopharmaceutical manufacturing industry.
Products and Services
-
Clinical and Commercial Drug Substance Manufacturing
This service caters to the production needs for drugs at both clinical trial and commercial scales. Scorpius Holdings, Inc. utilizes advanced manufacturing technologies to ensure high-quality drug substances are produced, meeting the stringent requirements of regulatory authorities and clients.
-
Release and Stability Testing Activities
Essential for confirming the quality and shelf life of pharmaceutical products, these activities involve rigorous testing protocols. Scorpius Holdings, Inc. provides comprehensive testing services to ensure that all products meet the required standards for efficacy and safety over time.
-
Upstream and Downstream Development and Optimization
This set of services focuses on optimizing the production process of biopharmaceuticals. Upstream development involves the cultivation of cells to produce the desired products, while downstream development is concerned with the purification and recovery of these products. Scorpius Holdings, Inc. aims to enhance both processes for efficiency and yield maximization.
-
Analytical Method Development Solutions
Scorpius Holdings, Inc. offers specialized solutions in developing and validating analytical methods. These services are crucial for ensuring that the manufacturing process remains consistent and that the final products are of high quality and free from impurities.
-
Cell Line Development, Testing, and Characterization Services
The company provides comprehensive services for the development, testing, and characterization of cell lines used in biopharmaceutical production. These services are critical for achieving efficient and reproducible manufacturing processes, ensuring the production of high-quality biologic drugs.
